The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results